Conagra Brands heads into tomorrow's Q4 earnings print having clawed back some ground, but with shorts still heavily positioned and analysts continuing to lower the bar.
The stock gained 4.2% on the week to close at $14.03 — its best weekly move in months, outpacing close peers. GIS added just 2.0% on the week, while KHC rose 4.6% and CPB fell 0.5%. The recovery lifts CAG above the mean analyst price target of $14.32, a striking reversal given most of the Street has been cutting targets rather than raising them.
Short sellers have eased their grip into the print, but the position remains large. Short interest dipped 5.2% on the week to 10.7% of the free float — still a high reading, and one that has grown 11.7% over the past month. The week-long retreat may reflect shorts locking in gains after a bruising stretch for the stock, or simply reducing event risk ahead of tomorrow's release. Borrow conditions offer no squeeze pressure either way: cost to borrow has fallen sharply, down 25% on the week to just 0.34%, and availability has expanded dramatically to 654% — meaning the lending pool holds more than six times as many shares available as are currently borrowed. That is the loosest borrow environment for CAG in at least a year, well above the 52-week low availability of 338%. Nothing in the lending market points to a short squeeze setup.
Options traders are not making a strong directional bet either. The put/call ratio at 0.56 is only marginally above its 20-day average of 0.53, producing a z-score of just 0.36 — entirely unremarkable. Notably, the PCR has been drifting lower all week from 0.59 at the start of the period, consistent with a market that is not aggressively hedging into the number. The 52-week high PCR of 0.96 provides context for how much more defensive the options market could be; right now it is not.
The Street remains uniformly cautious. Barclays cut its target to $16 from $18 this morning — the most recent action, maintaining Overweight but clearly reducing conviction. Every analyst who has moved since early June has cut. The mean target of $14.32 is barely above the current price, and several houses — Deutsche Bank at $12, Bernstein at $12 (Underperform), and Evercore ISI at $13 — imply downside from here. Forward EPS momentum ranks in just the 8th percentile over 30 days and the 26th over 90 days, while EV/EBITDA at 8.6x has crept up 0.25 turns over the past month as earnings estimates fell faster than the stock. The one bright spot bulls can point to is that value metrics remain supportive — price-to-book at 0.72x and an earnings yield above 12% argue the stock is cheap, but as noted in the bull case, cheap is likely to stay cheap until there is evidence of volume recovery.
Board-level insiders agreed with the value argument in April, when Chairman Richard Lenny and Director John Mulligan bought a combined $609k worth of stock around $14.30. That cluster of buying near current prices is the clearest expression of insider conviction — but it came roughly three months before tomorrow's print, and the stock has moved little since.
What matters most tomorrow is whether management can show any volume stabilisation in frozen and snacks, and whether the guidance range is wide enough to accommodate continued tariff and cost uncertainty without spooking a market that has already marked the stock down roughly 18% year-to-date.
See the live data behind this article on ORTEX.
Open CAG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
